Boehringer Lung Drug Wins U.S. FDA Advisory Panel Backing

Boehringer Ingelheim GmbH, the world’s biggest family-owned drugmaker, won the backing of U.S. regulatory advisers for a drug to treat a lung disease that is the nation’s third-leading cause of death.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.